RAMIRIS |
Phase II/III |
Ramucirumab plus Irinotecan/Leucovorin/5-FU versus Ramucirumab + Paclitaxel bei |
Matterhorn |
Phase III |
Eine randomisierte, doppelblinde, placebokontrollierte Phase-III-Studie zur |
DANTE III (Flot 8) |
Phase III |
A randomized, open-label Phase II/III efficacy and safety study of atezolizumab in combination with FLOT versus FLOT alone in patients with gastric cancer and adenocarcinoma of the oesophago-gastric junction and high immune responsiveness |
SAGA |
Phase I |
A phase Ib/II single-arm, multicenter study of sacituzumab-govitecan, a TROP-2 targeting antibody linked with SN38, for patients with metastatic esophagogastric adenocarcinoma Eudract Nr. 2023-505257-40 |
XPORT-MF-034 |
Phase III |
Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Eudract Nr. 2020-003883-19 |